CTOs on the Move

B-One

www.b1.co

 
A few individuals with decades of experience in the U.S. orthopedic industry,came together in 2015 because they saw the need for a first-class company that was Agile,creative and innovative in a global market subject to advancing technologies and changing policies.They had seen the successes of the large companies, but they had witnessed compromises that had to be made.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.b1.co
  • 636 Shelby Street 4th Floor
    Bristol, TN USA 37620
  • Phone: N/A

Executives

Name Title Contact Details

Funding

B-One raised $14M on 03/03/2020

Similar Companies

Miromatrix Medical

The Miromatrix Medical technology has the potential to enable the creation of fully biological replacement organs for the human body. In addition to the Company’s internal efforts focused on the development of its first product – a biological mesh for hernia repair – scientists around the globe are working with the Company’s technology and are taking critical steps toward the creation of human organs including the liver, lung, kidney, pancreas and heart. While our biological mesh development program has been conducted internally, our intent is for current and future products to be developed both at Miromatrix and in partnership with the best among those external groups already working with our technology in order to utilize this pre-existing expertise to develop individual products in the most efficacious, cost-effective and timely way possible.

Steth IO

Steth IO is a digital health startup bringing a convergence of technologies -- mobile, cloud, machine learning, and sensors -- to drive down the cost of healthcare.

Scientek Technology

Scientek Technology Corp. is a Delta, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthline Medical

Healthline Medical is a Baldwin Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Glaukos

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world`s leading causes of blindness. Glaukos has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. The company launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device, in the United States in 2012. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. Glaukos believes the iStent is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, the company completed an initial public offering and its shares are now traded on the New York Stock Exchange under the ticker symbol "GKOS". Founded in 1998, Glaukos is based in San Clemente, California.